Quantum chemical analysis of MHC-peptide interactions for vaccine design.
The development of an adequate immune response against pathogens is mediated by molecular interactions between different cell types. Among them, binding of antigenic peptides to the Major Histocompatibility Complex (MHC) molecule expressed on the membrane of antigen presenting cells (APCs), and their subsequent recognition by the T cell receptor have been demonstrated to be crucial for developing an adequate immune response. The present review compiles computational quantum chemistry studies about the electrostatic potential variations induced on the MHC binding region by peptide's amino acids, carried out with the aim of describing MHC-peptide binding interactions. The global idea is that the electrostatic potential can be represented in terms of a series expansion (charge, dipole, quadrupole, hexadecapole, etc.) whose three first terms provide a good local approximation to the molecular electrostatic 'landscape' and to the variations induced on such landscape by targeted modifications on the residues of the antigenic peptide. Studies carried out in four MHC class II human allele molecules, which are the most representative alleles of their corresponding haplotypes, showed that each of these molecules have conserved as well as specific electrostatic characteristics, which can be correlated at a good extent with the peptide binding profiles reported experimentally for these molecules. The information provided by such characteristics would help increase our knowledge about antigen binding and presentation, and could ultimately contribute to developing a logical and rational methodology for designing chemically synthesized, multi-antigenic, subunit-based vaccines, through the application of quantum chemistry methods.
Agudelo
W A
WA
Fundación Instituto de Immunología de Colombia, Carrera 50 No. 26-20, Bogotá DC, Colombia.
Patarroyo
M E
ME
D006680:HLA Antigens / Q000737:chemistry; D006649:Histocompatibility Antigens / Q000737:chemistry*; D006801:Humans; D010455:Peptides / Q000737:chemistry* / Q000276:immunology; D011485:Protein Binding; D011789:Quantum Theory; D055672:Static Electricity; D014612:Vaccines / Q000737:chemistry* / Q000276:immunology
D006680:HLA Antigens; D006649:Histocompatibility Antigens; D010455:Peptides; D014612:Vaccines
Biochimie. 2006 Sep;88(9):1307-11
16872734
EMBO J. 1990 Jun;9(6):1797-803
2189723
Biochem Biophys Res Commun. 2004 Oct 29;323(4):1265-77
15451434
Chem Rev. 2008 Sep;108(9):3656-705
18710292
J Cell Mol Med. 2008 Oct;12(5B):1915-35
19012725
J Pharmacol Sci. 2007 Dec;105(4):299-316
18094522
J Phys Chem A. 2009 Oct 1;113(39):10527-33
19775172
Brief Bioinform. 2007 Mar;8(2):96-108
17077136
J Exp Med. 1998 Oct 19;188(8):1511-20
9782128
J Phys Chem A. 2007 Nov 1;111(43):11134-40
17918915
Bioinformatics. 2006 Jul 15;22(14):e16-24
16873467
Immunity. 1997 Oct;7(4):473-81
9354468
J Mol Graph. 1996 Feb;14(1):33-8, 27-8
8744570
Acc Chem Res. 2008 Mar;41(3):377-86
18266328
J Med Chem. 2001 Oct 25;44(22):3572-81
11606121
Nature. 1993 Jul 1;364(6432):33-9
8316295
Nature. 1994 Mar 17;368(6468):215-21
8145819
Methods. 2004 Dec;34(4):436-43
15542369
J Exp Med. 2002 Mar 4;195(5):571-81
11877480
Curr Med Chem. 2005;12(24):2849-65
16305475
Med Chem. 2008 May;4(3):278-92
18473921
Immunogenetics. 2004 Mar;55(12):797-810
14963618
Biochem Biophys Res Commun. 2005 May 20;330(4):1162-7
15823565
Nature. 1995 Nov 30;378(6556):457-62
7477400